Longeveron reports Q3 2024 revenue up 177% YoY to $1.8M; HLHS trial enrollment >80%

Longeveron Inc.

2024-Q3 EPS reported -$2.71 revenue$1,789,000

Revenue for nine months ended Sept 30, 2024: $1.8M, up 177% YoY from $0.6M.
Net loss narrowed to $11.9M for nine months 2024 from $15.3M in 2023, a 23% improvement.
Cash and equivalents $22.8M; expects to fund operations through Q4 2025.
Phase 2b HLHS trial ELPIS II >80% enrolled; FDA confirmed pivotal trial acceptable for BLA if positive.
Phase 2a Alzheimer's data (CLEAR MIND) presented at AAIC and CTAD24.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.